Further clinical trials are necessary to investigate the safety of IL-1 inhibitors in patients with impaired kidney function, and the current study suggests the possible safe administration of IL-1 inhibitors in CKD patients by providing MR evidence. This evidence concerns the gene IL1A and chronic kidney disease.